Du är här

2014-04-08

Medigene AG: Medigene and Kora Healthcare sign agreement for the commercialisation of Veregen® in United Kingdom and Ireland

Medigene AG / Medigene and Kora Healthcare sign agreement for the
commercialisation ofVeregen® in United Kingdom and Ireland . Processed and
transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely
responsible for the content of this announcement.
Martinsried/Munich, 8 April 2014.
Medigene AG (Frankfurt, Prime Standard) and the pharmaceutical company Kora
Healthcare concluded an exclusive agreement for the supply and
commercialisation ofVeregen®for the treatment of genital warts in United
Kingdom and Ireland. Following marketing authorisation, Kora Healthcare will
promote and distribute the drug for the treatment of genital warts. Medigene
will receive a one-time upfront payment, revenues from milestone payments and
from the supply of the finished product, as well as royalties on the future
sales of Veregen®in the two countries.

Dr. Frank Mathias
, Chief Executive Officer of Medigene AG
, comments: "We are glad that we will now be able to open up the two important
pharma markets, the United Kingdom and Ireland, with this marketing
partnership. Kora Healthcare is a renowned pharmaceutical company in the
field of sexual health, and will approach all relevant target groups with the
drug. We have now established sales networks for Veregen®in all European
countries."

Margaret Larkin,
Chief Executive Officer
of Kora Healthcare
, adds: "This novel ointment for the topical treatment of genital warts
complements our product portfolio in Sexual Health and strengthens our
competitive position. We look forward to having an innovative product like
Veregen®to offer to our customers for the treatment of genital warts."

Veregen®is currently available in the USA, Germany, Austria, Switzerland,
Spain, Serbia, the Netherlands, Taiwan, Norway, Sweden, Czech Republic and
Slovakia. Marketing authorisations in numerous additional countries have been
granted. Medigene has entered into several marketing partnerships for
Veregen®across Europe, Asia, and America, and is planning to continue this
global licensing strategy to further tap the drug's market potential.
Submission of the marketing authorisation application for Veregen®in United
Kingdom and Ireland as well as several remaining European countries
participating in the mutual recognition procedure is planned for 2014.

About Veregen®:
Veregen®, a topical treatment for external genital or perianal warts, contains
a concentrate of catechins with a complex defined composition extracted from
green tea leaves. In its current treatment guidelines for sexually
transmitted diseases, the US Center for Disease Control and Prevention
recommends Sinecatechins 15% ointment (Veregen®) as a possible option for
treating genital warts. In addition, Sinecatechins 10%&15% ointment
(Veregen®) has been included in the current European guideline on the
treatment of genital warts, the 2012 European Guideline for the Management of
Anogenital Warts

About Kora Healthcare:
Kora Healthcare, a subsidiary of Immdal Limited, is a privately owned
healthcare and pharmaceutical company headquartered in the Republic of
Ireland. It is a rapidly growing company focused on the development and
commercialisation of a portfolio of products and services within the
therapeutic areas of Sexual Health and Clinical Nutrition. Strategically
committed to on-going growth and development, Kora Healthcare is actively
engaged in licensing, partnering, developing and marketing of specialty
prescription pharmaceuticals and consumer healthcare products. For more
information, please visit www.korahealthcare.com.

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. Medigene concentrates on
the development of personalized T cell immunotherapies with focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, Veregen®, which is distributed by
commercial partners companies. Medigene has various drug candidates in
clinical development and it is developing highly innovative treatment
platforms. Medigene's wholly-owned subsidiary, Trianta, is developing next
generation antigen-tailored dendritic cell (DC) vaccines, T cell receptor
(TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). For
more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements.
Medigene®EndoTAG®and Veregen®are registered trademarks of Medigene AG.
Polyphenon E®is a trademark of Mitsui Norin Co., Ltd.
These trademarks may be owned or licensed in select locations only.

Contact

Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please go
to:http://www.medigene.de/unsubscribe

Press release as PDF
http://hugin.info/132073/R/1775072/605223.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

HUG#1775072

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.